These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20932171)

  • 1. Tolerance and safety of nifurtimox in patients with chronic chagas disease.
    Jackson Y; Alirol E; Getaz L; Wolff H; Combescure C; Chappuis F
    Clin Infect Dis; 2010 Nov; 51(10):e69-75. PubMed ID: 20932171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Nifurtimox, a bright future for treatment of Chagas disease].
    Wolf A; Boulliat C; Coillot C; Rouault M; Gaillard K; Beranger C; Oliver M
    Med Trop (Mars); 2011 Apr; 71(2):131-3. PubMed ID: 21695868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
    Murcia L; Carrilero B; Albajar Viñas P; Segovia M
    Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
    [No Abstract]   [Full Text] [Related]  

  • 4. Antitrypanosomal therapy for chronic Chagas' disease.
    Bern C
    N Engl J Med; 2011 Jun; 364(26):2527-34. PubMed ID: 21714649
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapeutic experience in a Chagas disease center].
    Abramson R; Figueroa P
    Rev Med Chil; 2013 Nov; 141(11):1427-33. PubMed ID: 24718469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Allopurinol in the treatment of chronic Chagas' disease].
    Meirovich CI; Montrull HL; Gallerano RH; Sosa RR
    Arq Bras Cardiol; 1985 Sep; 45(3):217-23. PubMed ID: 3939099
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of Chagas' disease].
    Apt W
    Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
    [No Abstract]   [Full Text] [Related]  

  • 8. Current status of Chagas disease chemotherapy.
    Guedes PM; Silva GK; Gutierrez FR; Silva JS
    Expert Rev Anti Infect Ther; 2011 May; 9(5):609-20. PubMed ID: 21609270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States.
    Forsyth CJ; Hernandez S; Olmedo W; Abuhamidah A; Traina MI; Sanchez DR; Soverow J; Meymandi SK
    Clin Infect Dis; 2016 Oct; 63(8):1056-1062. PubMed ID: 27432838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment.
    Pérez-Molina JA; Sojo-Dorado J; Norman F; Monge-Maillo B; Díaz-Menéndez M; Albajar-Viñas P; López-Vélez R
    Acta Trop; 2013 Aug; 127(2):101-4. PubMed ID: 23583863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American trypanosomiasis (Chagas disease).
    Rassi A; Rassi A; Marcondes de Rezende J
    Infect Dis Clin North Am; 2012 Jun; 26(2):275-91. PubMed ID: 22632639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nifurtimox (Lampit) for Chagas disease.
    Med Lett Drugs Ther; 2024 Jul; 66(1707):e123-e124. PubMed ID: 39137168
    [No Abstract]   [Full Text] [Related]  

  • 13. Chagas disease. American trypanosomiasis.
    Kirchhoff LV
    Infect Dis Clin North Am; 1993 Sep; 7(3):487-502. PubMed ID: 8254156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy].
    Gallerano RR; Sosa RR
    Rev Fac Cien Med Univ Nac Cordoba; 2000; 57(2):135-62. PubMed ID: 12934232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
    Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
    Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina.
    Sosa Estani S; Segura EL
    Mem Inst Oswaldo Cruz; 1999; 94 Suppl 1():363-5. PubMed ID: 10677756
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chagas' disease: clastogenic effect of nifurtimox and benznidazole in children].
    Moya PR; Trombotto GT
    Medicina (B Aires); 1988; 48(5):487-91. PubMed ID: 3151216
    [No Abstract]   [Full Text] [Related]  

  • 18. Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2001-2021.
    Abbott A; Montgomery SP; Chancey RJ
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(10):371-374. PubMed ID: 35271563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation].
    Coura JR; de Abreu LL; Willcox HP; Petana W
    Rev Soc Bras Med Trop; 1997; 30(2):139-44. PubMed ID: 9148337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing antibody decline after chemotherapy of early chronic Chagas disease patients.
    Murphy N; Cardinal MV; Bhattacharyya T; Enriquez GF; Macchiaverna NP; Alvedro A; Freilij H; Martinez de Salazar P; Molina I; Mertens P; Gilleman Q; Gürtler RE; Miles MA
    Parasit Vectors; 2021 Oct; 14(1):543. PubMed ID: 34670602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.